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Abstract
Introduction Dutch cardiovascular disease (CVD) preven-
tion guidelines recommend the use of modified SCORE risk
charts to estimate 10-year risk of fatal and nonfatal CVD
(myocardial infarction, cerebrovascular disease and conges-
tive heart failure). This combined risk is derived from the
SCORE mortality risk using multipliers. These multipliers
have been shown to underestimate overall CVD risk. We
aimed to compare the current Dutch risk charts with charts
that estimate a broader range of clinically relevant CVD
using updated multipliers.
Methods We constructed new risk charts for 10-year CVD
using updated, recently published multipliers from the
EPIC-Norfolk study, based on ratios of fatal CVD to clin-
ically relevant CVD (fatal plus nonfatal CVD requiring
hospitalisation for ischaemic heart disease, cardiac failure,
cerebrovascular disease, peripheral artery disease, and aor-
tic aneurysm). Our primary outcome was the proportion
of the three risk categories, i. e. ‘high risk’ (>20% 10-year
risk), ‘intermediate risk’ (10–19%) and ‘low risk’ (<10%)
in the new risk charts as compared with the current risk
charts.
Results Applying the updated fatal CVD/clinical CVD mul-
tipliers led to a marked increase in the high-risk categories
(109 (27%) vs. 244 (61%), (p < 0.001)), an absolute in-
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crease of 229%. Similarly, the number of low-risk cate-
gories decreased (190 (48%) vs. 81 (20%) (p < 0.001)).
Conclusion The current Dutch risk charts seriously under-
estimate the risk of clinical CVD, even in the first 10 years.
Even when analyses are restricted to CVD events that re-
quired hospitalisation, true 10-year risks are more than dou-
ble the currently estimated risks. Future guidelines may be
revised to reflect these findings.
Keywords Cardiovascular disease · Risk assessment ·
Risk prediction · Epidemiology
Introduction
Current multidisciplinary guidelines on cardiovascular dis-
ease (CVD) risk management (CVRM) in the Netherlands
recommend using a modified version of the Systematic
COronary Risk Evaluation (SCORE) to estimate 10-year
risk of fatal and nonfatal CVD [1]. When exceeding a pre-
defined threshold (≥20%), it is recommended to initiate or
intensify preventive measures. The original SCORE chart
and algorithm on which the modified, current version is
based is the ‘low-risk’ SCORE [2], which estimates 10-
year risk of fatal CVD only. Using data from two different
national cohorts [1, 3, 4], multipliers have been calculated
to convert the risk of 10-year fatal CVD to the risk of 10-
year fatal and nonfatal CVD, including first nonfatal hospi-
talisations for myocardial infarction (MI), cerebrovascular
disease and congestive heart failure (CHF). These multipli-
ers are 5× the SCORE predicted fatal CVD risk for individ-
uals aged 35–45 years, 4× for individuals aged 45–65 years,
and 3× for individuals aged >65 years. Overall risk is pre-
sented in the charts, and coded by colour [1].
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These multipliers have not been validated in other large
population-based studies, and include only three clinical
manifestations of nonfatal CVD. Recently, we published
an analysis of the ratios of fatal CVD to total CVD in
the European Prospective Investigation of Cancer and Nu-
trition-Norfolk (EPIC-Norfolk), a large prospective pop-
ulation-based cohort in the UK [5]. In this study, we
observed a complex relationship between fatal CVD and
a broad range of clinically relevant (requiring hospitalisa-
tion) CVD (fatal and nonfatal CVD including ischaemic
heart disease (IHD), cerebrovascular disease, CHF, periph-
eral arterial disease and aortic aneurysm), with decreasing
fatal CVD to clinical CVD ratios with increasing age, and
with greater ratios for women in all age groups, suggesting
that such ratios are highly age- and sex-dependent.
Therefore, in our current study, we applied these new ra-
tios to the original low-risk SCORE charts to design a new,
updated risk chart, and compared the updated risk chart
with the current risk chart.
Methods
Source population
We used data from the EPIC-Norfolk prospective popula-
tion study, a cohort of 25,639 men and women aged 39–79
residing in the county of Norfolk in the UK. Details of
the study have been described elsewhere [6]. In brief, be-
tween 1993 and 1997, 77,630 adults were invited from gen-
eral practices to participate in the study. Of these, 25,639
(33%) provided signed informed consent for study partic-
ipation and attended a baseline health assessment. Dur-
ing this visit, data were collected on medical history, drug
use, anthropometrics, blood pressure, and laboratory mea-
sures. The participants’ National Health Service number
was used to identify hospitalisations through the East Nor-
folk Health Authority database. Vital status for all EPIC-
Norfolk participants was obtained through death certifica-
tion at the Office for National Statistics. The underlying
cause of death or hospital admission was coded by trained
nosologists according to the International Classification of
Diseases (ICD), Tenth Revision. The EPIC-Norfolk study
was approved by the Norfolk Local Research Ethics Com-
mittee and complies with the Declaration of Helsinki [6].
We report results for follow-up to 31 March 2008, a mean
follow-up of 11 years.
Study design
To compare the effect of applying different ratios to the
SCORE charts, we constructed a new, updated risk chart
using the ratios found in the EPIC-Norfolk study. These
ratios and the fatal and nonfatal CVD rates on which they
are based have recently been published [5].
In our analysis, fatal CVD was defined as death where
CVD was reported as the underlying cause of death on the
death certificate. Clinically manifest CVD was defined as
fatal CVD plus hospitalisation with CVD as the underlying
cause, including five different presentations of CVD (IHD,
CHF, cerebrovascular disease, peripheral artery disease, and
aortic aneurysm), hereafter referred to as ‘CVD-updated’.
The current risk charts include fatal CVD and nonfatal CVD
from three manifestations of CVD (MI, cerebrovascular dis-
ease, and CHF), hereafter referred to as ‘CVD-current’.
The SCORE risk charts consist of three levels of risk:
green (<10% risk of 10-year CVD), yellow (10–19% risk
of 10-year CVD), and red (≥20% risk of 10-year CVD),
which have consequences for the initiation or intensifica-
tion of risk management strategies. We aimed to quantify
the effect of applying the updated multipliers for clinically
manifest CVD (CVD-updated) to the current risk charts
(based on CVD-current) by comparing the number of pa-
tient categories within the three risk levels in the current risk
charts with the number of patient categories in the updated
risk charts.
Only EPIC-Norfolk participants who did not report a his-
tory of MI or cerebrovascular disease at the baseline health
assessment were included in our analysis. We excluded in-
dividuals with diabetes mellitus, as diabetes mellitus is not
included as a variable in the SCORE algorithm.
As the multipliers in the Dutch guideline are based on fa-
tal CVD and nonfatal CVD including only MI, cerebrovas-
cular disease and CHF, we performed a sensitivity analy-
sis. In this analysis, we calculated a second set of ratios
of fatal CVD to fatal and nonfatal CVD using only IHD,
cerebrovascular disease and CHF for the nonfatal CVD out-
comes in individuals aged 39–70 years.
Statistical methods
Baseline characteristics were summarised separately for
men and women, using numbers and percentages for cat-
egorical data, means, 95% confidence intervals (CI) and
standard deviations (SD) for continuous data with a normal
distribution, and median and interquartile range for con-
tinuous variables with a non-normal distribution. Ten-year
rates of fatal CVD and clinically relevant CVD were esti-
mated using the Kaplan-Meier method. Ratios of fatal CVD
to clinically relevant CVD (CVD-updated) were calculated
for the total population and in age groups (40–50, 50–55,
55–60, 60–65, 65–70), for men and women separately. In
individuals with a 10-year risk of fatal CVD >0%, we ap-
plied the ratios from our previous study (men 39–50 years
11.7, 50–55 years 9.9, 55–60 years 9.5, 65–70 years, 6.9;
women 39–50 years 28.5, 50–55 years 19.6, 55–60 years
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Table 1 Population characteristics of EPIC-Norfolk participants
Population characteristics Total Male Female
(n = 24,014) (n = 24,014) (n = 10,509) (n = 13,505)
Age, years 58.8 ± 9.3 59.0 ± 9.3 58.7 ± 9.3
Body mass index, kg/m2 26.3 ± 3.9 26.4 ± 3.3 26.2 ± 4.3
Current smokers 2836 (11.8) 1297 (12.3) 1539 (11.4)
Systolic blood pressure, mm Hg 135.2 ± 18.3 137.1 ± 17.5 133.7 ± 18.8
Diastolic blood pressure, mm Hg 82.4 ± 11.2 84.4 ± 11.1 80.9 ± 11.1
Total cholesterol, mmol/l 6.2 ± 1.2 6.0 ± 1.1 6.3 ± 1.1
LDL cholesterol, mmol/l 4.0 ± 1.0 3.9 ± 1.0 4.0 ± 1.1
HDL cholesterol, mmol/l 1.4 ± 0.4 1.2 ± 0.3 1.6 ± 0.4
Data are presented as number (percentage), mean ± standard deviation, or median (interquartile range)
LDL low-density lipoprotein, HDL high-density lipoprotein
17.8, 60–65 years 9.1, 65–70 years 6.4) to calculate risk
of clinically relevant CVD (CVD-updated) [5]. As no
ratio could be applied to risk levels of 0%, these were
marked as ‘<1%’ in the risk charts. Risks were coloured
in accordance with the current risk charts: green <10%;
yellow 10–19%; red ≥20%. In accordance with the current
guidelines, risk levels higher than 50% were described as
‘>50%’. To estimate the effects of adding the broader range
of clinically manifest CVD to the risk charts, we quantified
the number of risk categories by summarising numbers of
coloured squares in the current risk charts and our updated
CVD charts, which were compared using Fisher’s exact
tests. Statistical analyses were performed in SPSS 22 and
STATA 13.
Results
The selected EPIC-Norfolk study population consisted of
24,014 men (43.8%) and women (56.2%) without a history
of MI, cerebrovascular disease or diabetes mellitus. The
population characteristics are presented in Table 1. Mean
age was 58.8 (SD 9.3) years, and 11.8% were current smok-
ers. Mean body mass index, total cholesterol and LDL-
cholesterol were 26.3 kg/m2 (SD 3.9), 6.2 mmol/l (SD 1.2)
and 4.0 mmol/l (SD 1.1), respectively, which is slightly
above the levels recommended in primary prevention set-
tings. The rate of 10-year fatal CVD was 3.9% (900 events);
the rate of clinically relevant CVD was 21.2% (4978 fatal
or nonfatal events).
Overall, the multipliers were 3.7 times higher when using
the outcomes of CVD-updated (5 clinical manifestations)
as compared with CVD-current (3 clinical manifestations);
in women (4.9×) higher than in men (2.4×). Illustrating
this, Fig. 1 shows the current risk charts and the updated
CVD risk charts based on the multipliers from CVD-up-
dated. Whereas the current charts contain in total 109
(27%) red squares, i. e. signifying a combination of risk
factors amounting to a 10-year fatal and nonfatal CVD risk
of ≥20%, deemed as ‘high risk’, this number increased
to 244 (61%, p < 0.001) when accounting for clinically
relevant CVD, an absolute increase of 229%. Similarly,
the numbers of patient categories at ‘low risk’ (<10%) de-
creased from 190 (48%) to 81 (20%) (p < 0.001) when
accounting for clinically relevant CVD (Fig. 2).
In the sensitivity analysis, we limited the number of out-
come events to three instead of five clinical manifestations
of CVD (fatal CVD and nonfatal IHD, cerebrovascular dis-
ease, and CHF). In total, there were 1844 events when
using this outcome definition, amounting to a cumulative
event rate of 9.5% (95% CI 9.1–9.9). When calculating the
ratios of fatal CVD to this selection of clinical events, these
ratios remained markedly higher in the younger age groups
(Table 2) as compared with the current multipliers (Fig. 3).
In individuals aged 60 years or older, the multipliers were
more in agreement with the currently used multipliers.
Discussion
Our analysis shows that the current risk charts as recom-
mended by the Dutch CVRM guideline seriously underes-
timate the risk of nonfatal CVD, even in the first 10 years.
Applying multipliers to calculate nonfatal CVD from fatal
CVD using a greater number of clinical outcome events (5
versus 3) leads to a drastically higher risk estimation, es-
pecially in young individuals, and in women more than in
men. When the multipliers are applied to the current risk
charts, an increase is observed of 229% in the proportion
at ‘high risk’. Consequently, the current focus on a limited
number of vascular territories for nonfatal events in risk
stratification potentially leaves large numbers of individu-
als untreated, even though their risk of CVD is substantial.
The definition and choice of CVD events is essential in
any study investigating the relationship between fatal CVD
and different manifestations of nonfatal CVD. We believe
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Fig. 1 Risk charts of 10-year risk of CVD (Left panel: 10-year risk of fatal CVD and nonfatal myocardial infarction, cerebrovascular disease,
and congestive heart failure, as in the current Dutch preventive guidelines. Right panel: Updated risk chart for 10-year risk of clinically relevant
CVD (any fatal or nonfatal CVD, including ischaemic heart disease, cerebrovascular accident, congestive heart failure, peripheral artery disease,
and aortic aneurysm). Numbers are % 10-year risk. CVD cardiovascular disease)
Fig. 2 Risk stratification according to colour in the current risk charts
and in the updated CVD risk charts (CVD cardiovascular disease)
that for adequate counselling on CVD preventive strategies,
all outcomes that are relevant to patients should be included.
In our analysis, we only included events requiring hospi-
talisation, while milder CVD, i. e. peripheral artery disease
or CHF not requiring hospitalisation, were not included.
While these manifestations do not require hospitalisation,
they are relevant to patients, providers of healthcare, policy
makers, and insurance companies. Furthermore, in recent
decades, CVD mortality has shown a decline relative to
CVD morbidity, and the burden of total CVD is likely to
increase [7, 8]. Consequently, even our adjusted multipliers
are likely to underestimate true risk.
Individual lifetime risks of fatal and nonfatal CVD, in-
stead of 10-year risk, could potentially be more relevant
to patients and caregivers. Lifetime CVD mortality has
been shown to be markedly higher than 10-year risk [9].
However, 10-year risk estimation is a practical approach in
assessing risk, and helps caregivers evaluate whether pre-
ventive therapies should be initiated or may be postponed,
dependent on future reassessment.
The type of first nonfatal CVD event could potentially in-
fluence preventive strategies. The majority of first nonfatal
events or hospitalisations in our population were caused by
ischaemic CVD (77.6%), including IHD, ischaemic cere-
brovascular disease and peripheral arterial disease [5]. A re-
cent analysis in the same population has shown that differ-
ent risk factors have different impacts on atherosclerotic
CVD manifestations [10]. Therefore, in individuals with
a high risk-factor burden, or in which a sequential approach
to risk factor optimisation is desired, this could potentially
aid the choice of initial therapies (i. e. aggressive LDL-low-
ering to prevent coronary artery disease, intensified blood
pressure control to prevent peripheral artery disease and
cerebrovascular disease), taking into account each individ-
uals’ clinical circumstances [11, 12].
Several factors play a role when interpreting the differ-
ent versions of the SCORE risk charts. In a recent paper,
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Table 2 Cumulative 10-year CV mortality and CV mortality and nonfatal ischaemic heart disease/cerebrovascular disease/CHF by sex and age
in EPIC-Norfolk
Sex Age group 10-year CV mortality 10-year CV mortality and nonfatal IHD/
stroke/CHF
Ratio
N n KM rate 95%CI n KM rate 95%CI
Male 39–50 2219 15 0.7 (0.4–1.1) 104 4.8 (4.0–5.8) 6.9
50–55 1780 26 1.5 (1.0–2.2) 160 9.3 (8.1–10.8) 6.2
55–60 1637 34 2.1 (1.5–3.0) 190 12.3 (10.7–14.0) 5.9
60–65 1633 67 4.2 (3.4–5.4) 299 19.7 (17.8–21.8) 4.7
65–70 1622 127 8.3 (7.0–9.8) 384 26.3 (24.1–28.6) 3.2
Total 8891 269 3.1 (2.8–3.5) 1137 13.5 (12.8–14.3) 4.4
Female 39–50 3061 5 0.2 (0.07–0.4) 43 1.4 (1.1–1.9) 7.0
50–55 2333 11 0.5 (0.3–0.9) 71 3.2 (2.5–4.0) 6.4
55–60 2129 17 0.8 (0.5–1.3) 122 6.0 (5.1–7.1) 7.5
60–65 2014 43 2.2 (1.6–2.9) 175 9.3 (8.0–10.1) 4.2
65–70 1995 86 4.5 (3.6–5.5) 296 16.4 (14.7–18.2) 3.6
Total 11,206 162 1.4 (1.2–1.7) 707 6.4 (6.0–6.9) 4.6
CVD mortality is death from a cardiovascular disease. CVD mortality and nonfatal IHD/cerebrovascular disease/CHF is all fatal cardiovascular
disease or nonfatal IHD/ cerebrovascular disease/CHF requiring hospitalisation. Cumulative event rates were calculated using the Kaplan-Meier
method
Ratio is the ratio of CVD mortality/ CV mortality and nonfatal IHD/cerebrovascular disease/CHF of the Kaplan-Meier estimates
CVD cardiovascular disease, CI confidence interval, KM Kaplan-Meier, IHD ischaemic heart disease, CHF congestive heart failure
Fig. 3 Current score chart ratios compared with EPIC-Norfolk ra-
tios for CVD mortality and CVD mortality plus IHD, cerebrovascular
disease and CHF (CVD cardiovascular disease, IHD ischaemic heart
disease, CHF congestive heart failure)
we found that SCORE slightly overestimates mortality risk
(10–39% in men, 21–82% in women) in the UK [13]. This
was most prominent for fatal coronary heart disease (over-
estimation of 61%) as compared with fatal non-coronary
heart disease (a slight underestimation of 13%). With de-
creasing case fatality rates over time, the ratios between
mortality and morbidity are expected to increase. There-
fore, several factors simultaneously contribute to over- and
under-estimation of risk within the SCORE algorithm. In
addition, landmark trials have reported varying ratios of
fatal to nonfatal CVD, [14, 15] and it has been hypothesised
that these differences reflect diagnostic differences (such as
ascertainment and diagnostic thresholds) rather than un-
derlying disease differences [16]. The risk charts in their
original form were published in 2003, based on 12 large Eu-
ropean cohorts, with inclusion periods ranging from 1967
to 1991. Since the inclusion started in the earliest cohorts of
the original SCORE population (1967), therapeutic strate-
gies have changed considerably. While a comparison of the
effect of these changes is difficult to quantify across the
respective cohorts, such changes in therapeutic strategies
certainly influence the total burden of CVD and the rates of
fatal and nonfatal CVD. As a consequence of these chang-
ing event rates, several countries initially classified as high-
risk countries, including both the UK and the Netherlands,
have now been reclassified as low-risk countries [3, 13, 17].
Due to these temporal trends, we believe that findings in the
most recent cohort, i. e. EPIC Norfolk, may reflect current
event rates most accurately.
Furthermore, there are important differences in the pop-
ulation characteristics in the original SCORE cohort, as
compared with the EPIC-Norfolk, MORGEN and ERGO
cohorts (Tables 3 and 4), which should be taken into ac-
count when interpreting our results. The SCORE cohort
had more men as compared with the later cohorts, and
the prevalence of smoking was considerably higher. Also,
mean blood pressure was higher in the ERGO cohort as
compared with the other cohorts, and ERGO only included
individuals ≥55 years of age.
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Table 3 Baseline characteristics of the original SCORE cohort and EPIC-Norfolk
SCORE cohort2 (n = 205,178) EPIC-Norfolk (n = 24,014)
Inclusion years 1967–1991 1993–1997
Age, range 45–64 39–70
Men Women Men Women
n, (%) 117,098 (57) 88,080 (43) 10,509 (44) 13,505 (56)
Age, mean nr nr 59.0 (±9.3) 58.7 (±9.3)
Smoking, % 51 27 12.3 11.4
TC, mmol/l 6.1 6.0 6.0 (±1.1) 6.3 (±1.1)
HDL, mmol/l 1.3 1.2 1.2 (±0.4) 1.6 (±0.4)
SBP, mm Hg 139 133 137.1 (±17.5) 133.7 (±18.8)
BMI, kg/m2 nr nr 26.4 (±3.3) 26.2 (±4.3)
Data extracted from original publications (reference as number in superscript). Numbers are presented as mean and (±SD) (when available), range,
or percentage
nr not reported, TC total cholesterol, HDL high-density lipoprotein cholesterol, SBP systolic blood pressure, BMI body mass index
Table 4 Baseline characteristics of the MORGEN and ERGO cohorts
MORGEN3 (n = 32,887) ERGO4 (n = 6045)
Inclusion years 1987–1997 1990–1993
Age, range 37.5–62.5 ≥55
Men Women Men Women
n, (%) 15,457 (47) 17,430 (53) 2,287 (38) 3,758 (62)
Age, mean 46 (±6.5) 49 (±6.6) 67.9 (±8.3) 69.7 (±9.4)
Smoking, % 38 37 31.0 18.5
TC, mmol/l 5.7 (±1.1) 5.7 (±1.1) 6.3 (±1.2) 6.8 (±1.2)
HDL, mmol/l 1.1 (nr) 1.1 (nr) 1.2 (±0.3) 1.4 (±0.4)
SBP, mm Hg 126 (±15.9) 121 (±17) 139 (±22) 140 (±22)
BMI, kg/m2 26.0 (±3.4) 25.6 (±4.3) 25.6 (±3.0) 26.7 (±4.0)
Data extracted from original publications (reference as number in superscript). Numbers are presented as mean and (±SD) (when available), range,
or percentage
nr not reported, TC total cholesterol, HDL high-density lipoprotein cholesterol, SBP systolic blood pressure, BMI body mass index
Strengths and limitations
There are several strengths to our study. First, we performed
our analysis in a large, population-based cohort with long-
term follow-up. Detailed information on fatal and nonfatal
outcomes and hospitalisation was available, and we were
able to analyse event rates in large subgroups based on
age and sex. Second, the EPIC-Norfolk cohort is compa-
rable with a representative UK sample for anthropometric
variables, blood pressure and serum lipids [6]. It should
however be noted that the population in the Norfolk area is
healthier than the general UK population with a standard-
ised mortality ratio of 0.94 (source: Office for National
Statistics). Third, a large number of outcome events were
available, which were coded by trained nosologists accord-
ing to the relevant ICD codes, based on the underlying
cause of death or hospital admission. Previous validation
studies in this cohort indicated high specificity of such case
ascertainment [18].
Some aspects of our study warrant consideration. First,
the EPIC-Norfolk population study is a UK study. Ideally,
our analysis should have been performed in a contemporary
Dutch cohort. This is not available. However, both coun-
tries are currently categorised as low-risk countries, justify-
ing the use of the same SCORE algorithms and risk charts
in both populations. Second, CVD not requiring hospital-
isation, including ‘mild’ peripheral artery disease, ‘mild’
heart failure or stable angina pectoris, was not included in
our analysis. Not including these ‘milder’ manifestations
of CVD leads to an underestimation of the total risk of
CVD. Third, CVD other than IHD and cerebrovascular dis-
ease was not recorded at baseline in our cohort. Therefore,
we cannot exclude that some of the study participants in-
cluded in our analysis were already treated in the setting for
secondary prevention instead of primary prevention, mak-
ing them ineligible for risk stratification using the SCORE
charts. However, these individuals were similarly not ex-
cluded in the original SCORE cohorts [2].
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Conclusion
In conclusion, the 10-year risk of clinically relevant CVD
in an individual is significantly greater than is currently
estimated based on the current Dutch SCORE charts rec-
ommended by the CVRM guideline. Even when analyses
are restricted to CVD events that require hospitalisation,
true 10-year risks are more than double the currently es-
timated risks. Caution is advised when using the current
risk charts, especially in young individuals, as a low risk
according to the current risk charts may not reflect a low
risk of clinically relevant CVD. Future guidelines may need
to be revised to reflect these findings.
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